[
  {
    "ts": "2025-09-11T17:01:41+00:00",
    "headline": "Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best inexpensive stocks to buy according to hedge funds. On September 8, BioNTech (NASDAQ:BNTX) and Bristol Myers Squibb presented positive interim data from a global randomized Phase 2 trial of their investigational bispecific antibody, pumitamig (BNT327/BMS986545). The trial evaluated pumitamig in combination with chemotherapy for patients with […]",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-biontech-announce-170141724.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "4b1ab1d0-d3b2-3541-b40f-3b9f6e3c63b4",
      "content": {
        "id": "4b1ab1d0-d3b2-3541-b40f-3b9f6e3c63b4",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best inexpensive stocks to buy according to hedge funds. On September 8, BioNTech (NASDAQ:BNTX) and Bristol Myers Squibb presented positive interim data from a global randomized Phase 2 trial of their investigational bispecific antibody, pumitamig (BNT327/BMS986545). The trial evaluated pumitamig in combination with chemotherapy for patients with […]",
        "pubDate": "2025-09-11T17:01:41Z",
        "displayTime": "2025-09-11T17:01:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w_.mq2hxLlg_y2nUTx72ng--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6o8Kx8kFVS_oEolQVNGNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-biontech-announce-170141724.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-biontech-announce-170141724.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "BNTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-11T16:49:07+00:00",
    "headline": "BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY)",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best growth stocks under $50 to buy now. On September 8, BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY), retaining the price target of $47.00. The analyst attributed the rating to the performance of Cobenfy, the company’s new product, in the […]",
    "url": "https://finance.yahoo.com/news/bmo-capital-maintains-hold-bristol-164907085.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "703ecd31-b609-361c-9eed-6dc9020ea519",
      "content": {
        "id": "703ecd31-b609-361c-9eed-6dc9020ea519",
        "contentType": "STORY",
        "title": "BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY)",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best growth stocks under $50 to buy now. On September 8, BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY), retaining the price target of $47.00. The analyst attributed the rating to the performance of Cobenfy, the company’s new product, in the […]",
        "pubDate": "2025-09-11T16:49:07Z",
        "displayTime": "2025-09-11T16:49:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Why Investors View Bristol‑Myers Squibb (BMY) as a Safe Dividend Stock for Income",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w_.mq2hxLlg_y2nUTx72ng--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6o8Kx8kFVS_oEolQVNGNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmo-capital-maintains-hold-bristol-164907085.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmo-capital-maintains-hold-bristol-164907085.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-11T14:01:00+00:00",
    "headline": "Prothena Down 40% Year to Date: What Lies Ahead for the Stock?",
    "summary": "Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.",
    "url": "https://finance.yahoo.com/news/prothena-down-40-date-lies-140100126.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "ce624779-c7c7-38f6-b29e-10470f48f63a",
      "content": {
        "id": "ce624779-c7c7-38f6-b29e-10470f48f63a",
        "contentType": "STORY",
        "title": "Prothena Down 40% Year to Date: What Lies Ahead for the Stock?",
        "description": "",
        "summary": "Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.",
        "pubDate": "2025-09-11T14:01:00Z",
        "displayTime": "2025-09-11T14:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nURi29Wh6a5rz6SvQvvCDw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gUIojpJE4OxxDca8KkXZsA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/prothena-down-40-date-lies-140100126.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/prothena-down-40-date-lies-140100126.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "PRTA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-11T13:52:00+00:00",
    "headline": "Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?",
    "summary": "Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.",
    "url": "https://finance.yahoo.com/news/bristol-myers-loses-19-2-135200608.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "74a5d28e-ca61-3b1c-9ae2-d221fddd7608",
      "content": {
        "id": "74a5d28e-ca61-3b1c-9ae2-d221fddd7608",
        "contentType": "STORY",
        "title": "Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?",
        "description": "",
        "summary": "Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.",
        "pubDate": "2025-09-11T13:52:00Z",
        "displayTime": "2025-09-11T13:52:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-loses-19-2-135200608.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-loses-19-2-135200608.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-11T12:04:52+00:00",
    "headline": "Bristol-Myers Squibb (BMY): Assessing Valuation After New Pipeline Updates and Growth Strategy Reveal",
    "summary": "If you have been weighing what to do with Bristol-Myers Squibb (BMY), recent company updates might make you pause and reconsider your position. At the Morgan Stanley Healthcare Conference, Bristol-Myers Squibb laid out an ambitious, pipeline-driven growth strategy that includes launching seven new molecular entities in the next two years. At the same time, positive interim Phase 2 results with partner BioNTech in small cell lung cancer are fueling discussions about the company's ability to...",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-assessing-120452711.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ab3901b9-6159-3d72-adfa-952e943b7e3d",
      "content": {
        "id": "ab3901b9-6159-3d72-adfa-952e943b7e3d",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb (BMY): Assessing Valuation After New Pipeline Updates and Growth Strategy Reveal",
        "description": "",
        "summary": "If you have been weighing what to do with Bristol-Myers Squibb (BMY), recent company updates might make you pause and reconsider your position. At the Morgan Stanley Healthcare Conference, Bristol-Myers Squibb laid out an ambitious, pipeline-driven growth strategy that includes launching seven new molecular entities in the next two years. At the same time, positive interim Phase 2 results with partner BioNTech in small cell lung cancer are fueling discussions about the company's ability to...",
        "pubDate": "2025-09-11T12:04:52Z",
        "displayTime": "2025-09-11T12:04:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-assessing-120452711.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-assessing-120452711.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "BNTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-11T10:30:00+00:00",
    "headline": "China’s Multibillion-Dollar US Pharma Pipeline Draws Scrutiny in Washington",
    "summary": "China’s pharmaceutical sector, a minor player just years ago, has revved up into a global juggernaut faster than a Fuxing high speed train.",
    "url": "https://www.thedailyupside.com/industries/healthcare/chinas-multibillion-dollar-pharmaceutical-pipeline-to-the-us-scrutinized-in-washington/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "7a352a12-31c8-3c64-a32c-4123638ca031",
      "content": {
        "id": "7a352a12-31c8-3c64-a32c-4123638ca031",
        "contentType": "STORY",
        "title": "China’s Multibillion-Dollar US Pharma Pipeline Draws Scrutiny in Washington",
        "description": "",
        "summary": "China’s pharmaceutical sector, a minor player just years ago, has revved up into a global juggernaut faster than a Fuxing high speed train.",
        "pubDate": "2025-09-11T10:30:00Z",
        "displayTime": "2025-09-11T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/6bf51a1e8a60422878c0be673152f16a",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "Research staff members are shown working in a biotech lab at the Zhongguancun Science Park in China's Hebei Province.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ru60Zdn6FlFK3To3xKGTqw--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/6bf51a1e8a60422878c0be673152f16a.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UthPvGPx5uXzEFuuKjoKYA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/6bf51a1e8a60422878c0be673152f16a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/industries/healthcare/chinas-multibillion-dollar-pharmaceutical-pipeline-to-the-us-scrutinized-in-washington/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/china-multibillion-dollar-us-pharma-103000963.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]